

02-33000-25

Original Effective Date: 01/01/02

Reviewed: 01/22/26

Revised: 02/15/26

## Subject: Total Artificial Hearts and Implantable Ventricular Assist Devices

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

[Position Statement](#)

[Billing/Coding](#)

[Reimbursement](#)

[Program Exceptions](#)

[Definitions](#)

[Related Guidelines](#)

[Other](#)

[References](#)

[Updates](#)

### DESCRIPTION:

Heart failure may be the consequence of a number of differing etiologies, including ischemic heart disease, cardiomyopathy, congenital heart defects, or rejection of a heart transplant. The reduction of cardiac output is considered to be severe when systemic circulation cannot meet the body's needs under minimal exertion. Heart transplantation improves quality of life and survival; however, the number of candidates for transplant exceeds the supply of donor organs, thus compelling the development of mechanical devices.

The New York Heart Association (NYHA) developed a functional classification for heart disease. Each of the four classifications are described in the table below:

<b>Class I (mild)</b>	Has no limitations on clinical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea (shortness of breath).
<b>Class II (mild)</b>	Has slight limitations of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea.
<b>Class III (moderate)</b>	Has marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea.
<b>Class IV (severe)</b>	Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased.

## **Ventricular Assist Devices**

Implantable ventricular assist devices are attached to the native heart, which may have enough residual activity to withstand a device failure in the short term. In reversible conditions of heart failure, the native heart may regain some function, and weaning and explanting of the mechanical support system after months of use has been described. VADs can be classified as internal or external, electrically or pneumatically powered, and pulsatile or continuous flow. Initial devices were pulsatile, mimicking the action of a beating heart. More recent devices may use a pump, which provides continuous flow. Continuous flow devices may move blood in rotary or axial flow.

VADs are most commonly used to support the left ventricle but right ventricular and biventricular devices may be used. The device is larger than most native hearts, and therefore the size of the recipient is an important consideration; the pump may be implanted in the thorax or abdomen or remain external to the body. Inflow to the device is attached to the apex of the failed ventricle, while outflow is attached to the corresponding great artery (aorta for the left ventricle, a pulmonary artery for the right ventricle).

## **Percutaneous Ventricular Assist Devices**

Devices in which most of the system's components are external to the body are for short-term use (6 hours to 14 days) only, due to the increased risk of infection and need for careful, in-hospital monitoring. Some circulatory assist devices are placed percutaneously (ie, are not implanted). These may be referred to as pVADs. pVADs are placed through the femoral artery.

## **Total Artificial Hearts**

The total artificial heart (TAH) is a biventricular device which completely replaces the function of the diseased heart. An internal battery requires frequent recharging from an external power source. Many systems use a percutaneous power line, but a transcutaneous power-transfer coil allows for a system without lines traversing the skin, possibly reducing the risk of infection. Because the heart must be removed, failure of the device is synonymous with cardiac death.

**Summary and Analysis of Evidence:** An UpToDate review titled "Treatment of advanced heart failure with a durable mechanical circulatory support device" (Birks, Mancini; 2024) states "The long-term survival of patients who undergo durable MCS device placement is dependent on the patient's characteristics at implant, whether the patient remains eligible for transplant, and the type of device. For those with a ventricular assist device, in a randomized trial that compared the HeartMate III device with the HeartMate II device, five-year survival free of a major stroke in the HeartMate III group was 58 percent. In a large registry (INTERMACS) that included patients with ventricular assist device (VAD) support, patients with an initial bridge to transplantation or bridge to candidacy implant strategy had five-year survival of 52 and 51 percent, respectively, and patients with an initial destination therapy strategy had a five-year survival of 44 percent. In those with an artificial heart, outcomes are worse with artificial hearts than with LV assist devices (LVADs), but in some patients with biventricular failure, an artificial heart may be the only option for durable MCS. In a large registry (INTERMACS) that included patients with artificial heart support and that reported outcomes up to two years after implant, 34 percent of patients died, 53 percent had undergone heart transplantation, and 13 percent were alive with their device in place. The complications of durable MCS include stroke, major bleeding, major infection, device malfunction/pump thrombosis, and right HF. The risk of complications is based on

patient risk factors, long-term management of the patient, and characteristics of specific devices.” UpToDate review “Short-term mechanical circulatory assist devices” (Jeevanandam, Eisen; 2024) states “(p)ercutaneous mechanical circulatory support may be considered in (1) very high-risk percutaneous coronary intervention, including those with complex coronary artery disease involving a large territory and severe left ventricular dysfunction (ejection fraction <35 percent) or recent decompensated heart failure; (2) acute myocardial infarction complicated by acute ischemic mitral regurgitation or ventricular septal rupture and cardiogenic shock; (3) advanced right- and/or left-sided heart failure during the period of stabilization of a critically ill patient while making decisions about longer-term support (“bridge-to-a-bridge”); (4) support during high-risk percutaneous valve procedures; (5) support for patients referred for electrophysiologic procedures who have severe underlying left ventricular dysfunction and who may not tolerate sustained ventricular arrhythmias during the procedure; (6) patients with medically refractory (particularly ventricular) arrhythmias associated with ischemia; and (7) acute cardiac allograft failure or post-transplant right ventricular failure.”

## POSITION STATEMENT:

### Ventricular Assist Devices

The use of an FDA-approved or cleared [including Humanitarian Device Exemption (HDE)] implantable ventricular assist device (VAD), **meets the definition of medical necessity**:

- As a **bridge to heart transplantation** for adults or children who:
  - Are currently listed as heart transplant candidates, **OR**
  - Are undergoing evaluation to determine candidacy for heart transplant, **AND**
  - Are not expected to survive until a donor heart can be obtained
- As a **bridge to recovery** in the post-cardiotomy setting in members who are unable to be weaned off cardiopulmonary bypass.
- As **destination therapy** when the following criteria are met:
  - New York Heart Association (NYHA) Class III heart failure with dyspnea upon mild physical activity or NYHA Class IV
  - Left ventricular ejection fraction  $\leq 25\%$
  - Inotrope-dependent, **OR** cardiac index  $< 2.2$  liters/min/m<sup>2</sup>, while not on inotropes and also meeting **ONE** of the following:
    - On optimal medical management, based on current heart failure practice guidelines for at least 45 of the last 60 days and are failing to respond, **OR**
    - Advanced heart failure for at least 14 days and dependent on intra-aortic balloon pump for  $\geq 7$  days

The use of an FDA-approved or cleared [including Humanitarian Device Exemption (HDE)] percutaneous ventricular assist device **meets the definition of medical necessity** to provide short term circulatory support for:

- Cardiogenic shock, **OR**

- Acute myocardial infarction, **OR**
- High risk percutaneous coronary interventions (PCI)

The use of an FDA-approved or cleared [including Humanitarian Device Exemption (HDE)] right ventricular assist device **meets the definition of medical necessity** when both of the following are met:

- Device is used for temporary circulatory support for up to thirty days for individuals in cardiogenic shock due to acute right ventricular failure, **AND**
- Member is willing and able to be treated with heparin or an appropriate alternative anticoagulant

### **Total Artificial Hearts**

The use of an FDA-approved or cleared [including Humanitarian Device Exemption (HDE)] total artificial heart **meets the definition of medical necessity** as a bridge to transplantation when all of the following are met:

- Biventricular failure with no other reasonable medical or surgical treatment options, **AND**
- Ineligible for other univentricular or biventricular support devices, **AND**
- Currently listed as a heart transplant candidate or undergoing evaluation to determine candidacy for heart transplant, **AND**
- Not expected to survive until a donor heart can be obtained

Other applications of implantable ventricular devices or total artificial hearts, including the use of total artificial hearts as destination therapy, are considered **experimental or investigational**. There is insufficient clinical evidence in the peer reviewed literature to allow conclusions on health outcomes.

Accessories and supplies used with a mechanical circulatory assist device **meet the definition of medical necessity** when criteria for the mechanical circulatory assist device are met.

## **BILLING/CODING INFORMATION:**

### **CPT Coding:**

33927	Implantation of a total replacement heart system (artificial heart) with recipient cardiectomy
33928	Removal and replacement of total replacement heart system (artificial heart)
33929	Removal of a total replacement heart system (artificial heart) for heart transplantation (List separately in addition to code for primary procedure)
33975	Insertion of ventricular assist device; extracorporeal, single ventricular
33976	Insertion of ventricular assist device; extracorporeal, biventricular
33977	Removal of ventricular assist device; extracorporeal single ventricular
33978	Removal of ventricular assist device; extracorporeal biventricular
33979	Insertion of ventricular assist device, implantable intracorporeal, single ventricle

33980	Removal of ventricular assist device, implantable intracorporeal, single ventricle
33981	Replacement of extracorporeal ventricular assist device, single or biventricular, pump(s), single or each pump
33982	Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle, without cardiopulmonary bypass
33983	Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle, with cardiopulmonary bypass
33990	Insertion of ventricular assist device, percutaneous, including radiological supervision and interpretation; left heart, arterial access only
33991	Insertion of ventricular assist device, percutaneous, including radiological supervision and interpretation; left heart, both arterial and venous access, with transeptal puncture
33992	Removal of percutaneous left heart ventricular assist device, arterial or arterial and venous cannula(s), at separate and distinct session from insertion
33993	Repositioning of percutaneous right or left heart ventricular assist device with imaging guidance at separate and distinct session from insertion
33995	Insertion of ventricular assist device, percutaneous, including radiological supervision and interpretation; right heart, venous access only
33997	Removal of percutaneous right heart ventricular assist device, venous cannula, at separate and distinct session from insertion

#### HCPCS Coding:

L8698	Miscellaneous component, supply or accessory for use with total artificial heart system
Q0477	Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0478	Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type
Q0479	Power module for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0480	Driver for use with pneumatic ventricular assist device, replacement only
Q0481	Microprocessor control unit for use with electric ventricular assist device, replacement only
Q0482	Microprocessor control unit for use with electric/pneumatic combination ventricular assist device, replacement only
Q0483	Monitor/display module for use with electric ventricular assist device, replacement only
Q0484	Monitor/display module for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0485	Monitor control cable for use with electric ventricular assist device, replacement only
Q0486	Monitor control cable for use with electric/pneumatic ventricular assist device, replacement only
Q0487	Leads (pneumatic/electrical) for use with any type electric/pneumatic ventricular assist device, replacement only
Q0488	Power pack base for use with electric ventricular assist device, replacement only
Q0489	Power pack base for use with electric/pneumatic ventricular assist device, replacement only

Q0490	Emergency power source for use with electric ventricular assist device, replacement only
Q0491	Emergency power source for use with electric/pneumatic ventricular assist device, replacement only
Q0492	Emergency power supply cable for use with electric ventricular assist device, replacement only
Q0493	Emergency power supply cable for use with electric/pneumatic ventricular assist device, replacement only
Q0494	Emergency hand pump for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0495	Battery/power pack charger for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0496	Battery, other than lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0497	Battery clips for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0498	Holster for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0499	Belt/vest/bag for use to carry external peripheral components of any type ventricular assist device, replacement only
Q0500	Filters for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0501	Shower cover for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0502	Mobility cart for pneumatic ventricular assist device, replacement only
Q0503	Battery for pneumatic ventricular assist device, replacement only, each
Q0504	Power adapter for pneumatic ventricular assist device, replacement only, vehicle type
Q0506	Battery, lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0507	Miscellaneous supply or accessory for use with an external ventricular assist device
Q0508	Miscellaneous supply or accessory for use with an implanted ventricular assist device
Q0509	Miscellaneous supply or accessory for use with any implanted ventricular assist device for which payment was not made under Medicare Part A

## REIMBURSEMENT INFORMATION:

None applicable.

## PROGRAM EXCEPTIONS:

**Federal Employee Program (FEP):** Follow FEP guidelines.

**State Account Organization (SAO):** Follow SAO guidelines.

**Medicare Advantage Products:** The following National Coverage Determination (NCD) was reviewed on the last guideline reviewed date: Ventricular Assist Devices (20.9.1) located at cms.gov.

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#)

## DEFINITIONS:

**Cardiac index:** One of many ways to describe the status of the heart's function; relies on cardiac output (CO), and turns cardiac output into a normalized value that accounts for body size. CI uses the following formula:  $\text{Cardiac Output} / \text{Body Surface Area} = (\text{Heart Rate} * \text{Stroke Volume}) / \text{Body Surface Area}$ .

**Cardiogenic shock (cardiac shock):** A serious condition that occurs when the heart cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs.

**Destination therapy:** the use of a ventricular assist device (VAD) for long-term, permanent support in those who are not candidates for transplant.

**Humanitarian Device Exemption (HDE):** a device that is intended to benefit persons by treating or diagnosing a disease or condition that affects or is manifested in fewer than 4,000 people in the United States per year.

**Inotropic support:** medications to help the heart pump more effectively.

**Intra-aortic balloon pump:** a machine that helps the heart pump; a catheter threaded into the aorta is equipped with a tip that helps pump blood out of the heart; does not require open chest surgery for placement.

## RELATED GUIDELINES:

**Heart Transplant, 02-33000-23**

**Heart and Lung transplant, 02-33000-24**

## OTHER:

Available mechanical circulatory support devices (may not be an all inclusive list)

**Note:** The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

### Ventricular assist devices

#### Heart Assist® 5 Pediatric VAD FDA approval:

- Temporary left side mechanical circulatory support as a bridge to cardiac transplantation for pediatric individuals

- 5-16 years old
- BSA  $\geq 0.7\text{m}^2$  and  $< 1.5\text{m}^2$ )
- NYHA class IV end stage heart failure
- Refractory to medical therapy
- Is a listed candidates for cardiac transplantation

**HeartMate II® FDA approval:**

- As destination therapy with NYHA class IIIB or IV end-stage left ventricular failure who have received optimal medical therapy for at least 45 of the last 60 days, and are not candidates for cardiac transplantation
- Life expectancy of less than 2 years
- Intended for use both inside and outside the hospital, or for transportation of those with ventricular assist devices via ground ambulance, fixed-wing aircraft, or helicopter

**HeartMate 3™ Left Ventricular Assist System FDA approval:**

- Short-term hemodynamic support (bridge to transplant or bridge to myocardial recovery)
- Short-term or long-term mechanical circulatory support (e.g., bridge to transplant, bridge to myocardial recovery, or destination therapy) in adults and children with advanced refractory left ventricular heart failure

**Berlin Heart EXCOR® Pediatric VAD FDA approval:**

- For bridge to transplant for pediatric individuals
- Severe isolated left ventricular or biventricular dysfunction
- Candidate for cardiac transplant
- Requires circulatory support

**HeartWare® Ventricular Assist System FDA approval:**

- For hemodynamic support in advanced, refractory left ventricular heart failure, as a bridge to cardiac transplantation (BTT)
- For bridge to myocardial recovery
- As destination therapy (DT) in individuals for whom subsequent transplantation is not planned

**Percutaneous ventricular assist devices**

**Impella® 2.5, Impella® 5.0, Impella® 5.5 with SmartAssist, Impella CP®, and Impella CP with SmartAssist® FDA approval:**

- As temporary ventricular support intended for short term use ( $\leq 4$  days for the Impella 2.5 and Impella CP, and  $\leq 6$  days for the Impella 5.0 and Impella LD) for treatment of ongoing

cardiogenic shock that occurs immediately (<48 hours) following acute myocardial infarction or open heart surgery, or

- In the setting of cardiomyopathy, including peripartum cardiomyopathy, or myocarditis
- Cardiogenic shock is a result of isolated left ventricular failure that is not responsive to optimal medical management and conventional treatment measures (these may include volume loading and use of pressors and inotropes, with or without IABP)
- Impella® CP is indicated for use during high risk percutaneous coronary interventions

**Impella® RP system FDA approval:**

- Temporary right ventricular support for up to 14 days for individuals with a body surface area  $\geq 1.5\text{m}^2$  for the following indications:
- Acute right heart failure or decompensation following left ventricular assist device implantation
- Myocardial infarction
- Heart transplant
- Open-heart surgery

**TandemHeart® FDA approval:**

- Temporary left ventricular bypass of  $\leq 6$  hours

**Total artificial hearts**

**SynCardia Temporary Total Artificial Heart (with Freedom® Driver System) FDA approval:**

- For use inside the hospital as a bridge to transplant in cardiac transplant-eligible candidates at risk of imminent death from biventricular failure.

**AbioCor® Implantable Replacement Heart System FDA approval (via HDE process):**

- Severe biventricular end stage heart disease individuals who are not cardiac transplant candidates
- Are younger than 75 years of age
- Require multiple inotropic support
- Are not treatable by left ventricular assist device (LVAD) destination therapy
- Are not weanable from biventricular support if on such support

**Right ventricular assist devices**

**Centrimag® Right Ventricular Assist Device FDA approval (via HDE process):**

- Temporary circulatory support for up to 14 days for individuals in cardiogenic shock due to acute right ventricular failure

## REFERENCES:

1. Awad WI, Bashir M. Mechanical circulatory support-Challenges, strategies, and preparations. *J Card Surg.* 2021 May;36(5):1723-1728. doi: 10.1111/jocs.15301. Epub 2021 Jan 13.
2. Baran DA, Billia F, Randhawa V, Cowger JA, Barnett CM, Chih S, Ensminger S, Hernandez-Montfort J, Sinha SS, Vorovich E, Proudfoot A, Lim HS, Blumer V, Jennings DL, Reshad Garan A, Renedo MF, Hanff TC, Kanwar MK; Consensus Conference participants/collaborators. Consensus statements from the International Society for Heart and Lung Transplantation consensus conference: Heart failure-related cardiogenic shock. *J Heart Lung Transplant.* 2024 Feb;43(2):204-216. doi: 10.1016/j.healun.2023.10.007. Epub 2023 Dec 8.
3. Blue Cross Blue Shield Association Evidence Positioning System®. 7.03.11 - Total Artificial Hearts and Implantable Ventricular Assist Devices, 11/25.
4. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Ventricular Assist Devices (20.9.1) (12/01/20).
5. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Artificial Hearts and Related Devices (20.9) (RETIRED 04/10/23).
6. Cheng JM, Corstiaan A, Hoeks SE, van der Ent M, Jewbali LSD, van Domburg RT, Serruys PW. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. *European Heart Journal* (2009) 30, 2102–2108.
7. Chung JS, Emerson D, Megna D, Arabia FA. Total artificial heart: surgical technique in the patient with normal cardiac anatomy. *Ann Cardiothorac Surg.* 2020;9(2):81-88. doi:10.21037/acs.2020.02.09.
8. ClinicalTrials.gov. Abiocr Implantable Replacement Heart. Verified by Abiomed Inc., April 2008. Identifier: NCT00669357.
9. ClinicalTrials.gov. SynCardia CardioWest TAH-t Postmarket Surveillance Study. Sponsored by SynCardia. Identifier: NCT00614510.
10. ClinicalTrials.gov. NCT01415869. Occult Gastrointestinal Bleeding in Non-pulsatile Left Ventricular Assist Device (VAD) Patients. Last Updated on 08/08/11 by Mayo Clinic.
11. ClinicalTrials.gov. NCT01185691. Investigating the Role of Impella 2.5 System in Acutely Decompensated Chronic Heart Failure Patients (RELIEF I). Last Updated on March 18, 2011 by Abiomed, Inc.
12. ClinicalTrials.gov. NCT01319760: MINI-AMI: Minimizing Infarct Size With Impella 2.5 Following PCI for Acute Myocardial Infarction. Accessed on 04/26/13.
13. ClinicalTrials.gov. NCT00972270: Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation (PERMIT1).
14. ClinicalTrials.gov. NCT00972270: Trial Using Impella LP 2.5 System in Patients With Acute Myocardial Infarction Induced Hemodynamic Instability (RECOVER II).
15. ClinicalTrials.gov. NCT00314847: Comparison of Standard Treatment Versus Standard Treatment Plus Extracorporeal Life Support (ECLS) in Myocardial Infarction Complicated With Cardiogenic Shock.
16. ClinicalTrials.gov. NCT01633502: Danish Cardiogenic Shock Trial (DanShock).
17. ClinicalTrials.gov. NCT01185691: Investigating the Role of Impella 2.5 System in Acutely Decompensated Chronic Heart Failure Patients (RELIEF I).
18. ClinicalTrials.gov. NCT01777607: The Use of Impella RP Support System in Patients With Right Heart Failure.
19. ClinicalTrials.gov. NCT00596726: RECOVER I Impella RECOVER LP/LD 5.0 Support System Safety and Feasibility Study.

20. ClinicalTrials.gov. NCT00562016: Protect II, A Prospective, Multicenter Randomized Controlled Trial (PROTECT II).
21. ClinicalTrials.gov. NCT00417378: Efficacy Study of LV Assist Device to Treat Patients With Cardiogenic Shock (ISAR-SHOCK).
22. ClinicalTrials.gov. NCT00534859: PROTECT I, A Prospective Feasibility Trial Investigating the Use of IMPELLA RECOVER LP 2.5 System in Patients Undergoing High Risk PCI.
23. Cook JA, et al. The total artificial heart. *J Thorac Dis.* 2015 Dec;7(12):2172-80.
24. Cubeddu RJ, MD, Lago R, Horvath SA, Vignola PA, O'Neill W, Palacios IF. Expert Review: Use of the Impella 2.5 system alone, after and in combination with an intra-aortic balloon pump in patients with cardiogenic shock: case description and review of the literature. *EuroIntervention* 2012; 7:1453-1460.
25. ECRI. Target Database Report: Magnetically levitated ventricular assist device (VAD) as a bridge to decision. Plymouth meeting PA: ECRI, (11/07).
26. ECRI. Target Database Report: Permanent Total Artificial Heart for Irreversible Heart Failure Plymouth meeting PA: ECRI, (06/04).
27. ECRI. Target Database Report: Permanent Total Artificial Heart (TAH) for Irreversible Heart Failure Plymouth meeting PA: ECRI, (02/08).
28. ECRI. Target Database Report: Total Artificial Heart as Bridge to Transplantation. Plymouth meeting PA: ECRI (01/07) Updated 02/06/07.
29. ECRI. Target Database Report: Ventricular assist devices as destination therapy for irreversible heart failure. Plymouth meeting PA: ECRI (11/03).
30. ECRI. Target Database Report: Ventricular Assist Devices for Heart Failure (long-term to heart transplant) Plymouth meeting PA: ECRI, (02/00).
31. ECRI. Target Database Report: Ventricular Assist Devices for Heart Failure (short-term bridge to recovery) Plymouth meeting PA: ECRI, (03/00).
32. ECRI Institute Emerging Technology Evidence Report: Total Artificial Heart as Bridge to Transplantation and Destination Therapy. December 2012.
33. ECRI Institute Emerging Technology Report: Miniature Intracardiac Pump for Acute Heart Failure. January 2012.
34. ECRI Institute Health Technology Forecast: More data presented at ACC confirm miniature heart pump failed to meet primary endpoints in trial. April 2011.
35. Edoardo Gronda, MD, Robert C. Bourge, MD, Maria Rosa Costanzo, MD, Mario Deng, MD, Donna Mancini, MD, Luigi Martinelli, MD, and Guillermo Torre-Amione, MD. Heart Rhythm Considerations in Heart Transplant Candidates and Considerations for Ventricular Assist Devices: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates – 2006. *The Journal of Heart and Lung Transplantation.* Volume 25, Issue 9, pages 1024 – 1042. September 2006.
36. Esposito ML, Kapur NK. Acute mechanical circulatory support for cardiogenic shock: the "door to support" time. *F1000Res.* 2017 May 22;6:737.
37. Ganyukov V, Tarasov R. High risk percutaneous coronary interventions-significance of left ventricular assist device for clinical practice. *J Thorac Dis.* 2015 Oct;7(10):1716-8.
38. Glenn N et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation.* 2011;124:e574-e651.

39. Gregory D et al. A Value-Based Analysis of Hemodynamic Support Strategies for High-Risk Heart Failure Patients Undergoing a Percutaneous Coronary Intervention. *Am Health Drug Benefits*. 2013;6(2):88-99.
40. Hayes Inc. Hayes Technology Brief. Percutaneous Extracorporeal Transseptal Ventricular Support Using the TandemHeart® PTVA® System (CardiacAssist Inc.) for Cardiogenic Shock and High-Risk Cardiac Interventions. Lansdale, PA. Hayes Inc. 03/07/07. Updated 03/18/08.
41. HAYES Inc. Medical Technology Directory: Total Artificial Heart, temporary or Permanent Biventricular Support Device Lansdale, PA. Hayes Inc. 07/18/05, updated 07/11/07.
42. HAYES Inc. Medical Technology Directory: Ventricular Assist Devices. Lansdale, PA. Hayes Inc. 05/HAYES Medical Technology Directory: "Ventricular Assist Devices" 05/06/05, updated 05/11/06.
43. Health Quality Ontario. Percutaneous Ventricular Assist Devices: A Health Technology Assessment. *Ont Health Technol Assess Ser*. 2017 Feb 7;17(2):1-97.
44. Heatley G, Sood P, et al. Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol. *J Heart Lung Transplant*. 2016 Apr;35(4):528-36.
45. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2022 May 3;79(17):e263-e421. doi: 10.1016/j.jacc.2021.12.012. Epub 2022 Apr 1. Erratum in: *J Am Coll Cardiol*. 2023 Apr 18;81(15):1551.
46. Hernandez, Arian F., Shea, Alisa M., Milano, Carmelo A.; et al. Long-term Outcomes and Costs of Ventricular Assist Devices Among Medicare Beneficiaries. *JAMA*. 2008; 300(20):2398-2406.
47. Immohr MB, Boeken U, Mueller F, et al. Complications of left ventricular assist devices causing high urgency status on waiting list: impact on outcome after heart transplantation. *ESC Heart Fail*. 2021 Apr;8(2):1253-1262. doi: 10.1002/ehf2.13188. Epub 2021 Jan 21.
48. Institute for Clinical Systems Improvement; Technology Assessment abstract: "Left Ventricular Assist Devices as Permanent Implants" (05/02).
49. Jorde UP, Shah AM, Sims DB, et al. Continuous-Flow Left Ventricular Assist Device Survival Improves With Multidisciplinary Approach. *Ann Thorac Surg*. 2019;108(2):508-516. doi:10.1016/j.athoracsur.2019.01.063. PMID: 30853587.
50. Joyce LD, Joyce DL. Total artificial heart: neurological complications. *Ann Cardiothorac Surg*. 2020;9(2):121-123. doi:10.21037/acs.2020.02.14.
51. Kazui T, et al. Minimally invasive approach for percutaneous CentriMag right ventricular assist device support using a single PROTEKDuo Cannula. *J Cardiothorac Surg*. 2016 Aug 4;11(1):123.
52. Kilic A. The future of left ventricular assist devices. *J Thorac Dis*. 2015 Dec;7(12):2188-93.
53. Kilic A, et al. Dealing with surgical left ventricular assist device complications. *J Thorac Dis*. 2015 Dec;7(12):2158-64.
54. La Torre MW, Centofanti P, Attisani M, Patanè F, Rinaldi, M. Posterior Ventricular Septal Defect in Presence of Cardiogenic Shock Early Implantation of the Impella Recover LP 5.0 as a Bridge to Surgery. © 2011 by the Texas Heart © Institute, Houston. Volume 38, Number 1, 2011.
55. Maini B et al. Real-World Use of the Impella 2.5 Circulatory Support System in Complex High-Risk Percutaneous Coronary Intervention: The USpella Registry. *Catheterization and Cardiovascular Interventions* 80:717–725 (2012).
56. Matsumiya G. Right Ventricular Failure – A Continuing Problem in the New Era of Left Ventricular Assist Device Therapy. *Circulation Journal* Vol.76, December 2012.

57. McMurray JJ, Adamopoulos S, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. *Eur J Heart Fail.* 2012 Aug;14(8):803-69.
58. Mehra MR, Uriel N, Naka Y, Cleveland JC Jr, Yuzefpolskaya M, et al; MOMENTUM 3 Investigators. A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. *N Engl J Med.* 2019 Apr 25;380(17):1618-1627. doi: 10.1056/NEJMoa1900486. Epub 2019 Mar 17.
59. Meyer DM, Nayak A, Wood KL, Blumer V, Schettle S, Salerno C, Koehl D, Cantor R, Kirklin JK, Jacobs JP, Cascino T, Pagani FD, Kanwar MK. The Society of Thoracic Surgeons Intermacs 2024 Annual Report: Focus on Outcomes in Younger Patients. *Ann Thorac Surg.* 2025 Jan;119(1):34-58. doi: 10.1016/j.athoracsur.2024.10.003. Epub 2024 Oct 21. PMID: 39442906.
60. Moscardelli S, Masoomi R, Villablanca P, Jabri A, Patel AK, Moroni F, Azzalini L. Mechanical Circulatory Support for High-Risk Percutaneous Coronary Intervention. *Curr Cardiol Rep.* 2024 Apr;26(4):233-244. doi: 10.1007/s11886-024-02029-2. Epub 2024 Feb 26. PMID: 38407792.
61. National Heart Lung and Blood Institute Website. Health topics: Cardiogenic shock. Available at: <http://www.nhlbi.nih.gov>.
62. National Heart Lung and Blood Institute Website. Diseases and conditions index: what is a total artificial heart? Available at: <http://www.nhlbi.nih.gov>.
63. National Heart Lung and Blood Institute Website. Diseases and conditions index: what is a ventricular assist device? Available at: <http://www.nhlbi.nih.gov>.
64. National Institute for Health and Clinical Excellence. Interventional Procedure Guidance 177: Short-term circulatory support with left ventricular assist devices as a bridge to cardiac transplantation or recovery. June 2006.
65. Phillips CT, Tamez H, Tu TM, Yeh RW, Pinto DS. Novel Method for Exchange of Impella Circulatory Assist Catheter: The "Trojan Horse" Technique. *J Invasive Cardiol.* 2017 Jul;29(7):250-252.
66. Roger VL et al. Executive Summary: Heart Disease and Stroke Statistics--2012 Update : A Report From the American Heart Association. *Circulation.* 2012;125:188-197.
67. Rose EA MD, et al. Long-term Use of a Left Ventricular Assist Device for End-Stage Heart Failure". *N Engl J Med* 2001; 345(20): 1435 – 1443.
68. Saeed D, Feldman D, Banayosy AE, Birks E, Blume E, Cowger J, Hayward C, Jorde U, Kremer J, MacGowan G, Maltais S, Maybaum S, Mehra M, Shah KB, Mohacsi P, Schweiger M, Schroeder SE, Shah P, Slepian M, Tops LF, Alvarez P, Arabia F, Aslam S, Benson-Louis L 4th, Birati E, Buchholz HW, Cedars A, Christensen D, Ciarka A, Coglianese E, Cogswell R, Cook J, Copeland J, Costello JG, Drakos SG, Eghtesady P, Elliot T, Estep JD, Eulert-Grehn JJ, Fabrizio R, Garbade J, Gelow J, Guglin M, Hernandez-Montfort J, Horstmanshof D, John R, Kanwar M, Khaliel F, Kim G, Kumar S, Lavee J, Leache M, Leprince P, Lim S, Loforte A, Maly J, Najjar S, Netuka I, Pamboukian SV, Patel SR, Pinney S, Pluym CV, Potapov E, Robson D, Rochlani Y, Russell S, Sandau K, Sandoval E, Sayer G, Schettle S, Schibilsky D, Schlöglhofer T, Schmitto J, Siddique A, Silvestry S, Slaughter MS, Sun B, Takayama H, Tedford R, Teuteberg JJ, Ton VK, Uriel N, Vierecke J, Zimpfer D, D'Alessandro D. The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update. *J Heart Lung Transplant.* 2023 Jul;42(7):e1-e222. doi: 10.1016/j.healun.2022.12.004. Epub 2023 May 25.
69. Saffarzadeh A, Bonde P. Options for temporary mechanical circulatory support. *J Thorac Dis.* 2015 Dec;7(12):2102-11.
70. Saxena P, Marasco SF. Tunneling a Pulmonary Artery Graft: A Simplified Way to Insert and Remove a Temporary Right Ventricular Assist Device. *Tex Heart Inst J.* 2015 Dec 1;42(6):540-2.
71. Schubert SA, Soleimani B, Pae WE. Case Report: Hemolysis and Pulmonary Insufficiency following Right Ventricular Assist Device Implantation. *Case Reports in Transplantation* Volume 2012, Article ID 376384.

72. Shah D, Sen J. Mechanical Circulatory Support in Cardiogenic Shock: A Narrative Review. *Cureus*. 2024 Sep 13;16(9):e69379. doi: 10.7759/cureus.69379.
73. Sjauw KD, Engström AE, Vis MM, Boom W, Baan Jr. J, de Winter RJ, Tijssen JGP, Piek JJ, Henriques JPS. Efficacy and timing of intra-aortic counterpulsation in patients with ST-elevation myocardial infarction complicated by cardiogenic shock. *Neth Heart J* (2012) 20:402–409.
74. Slaughter, Mark S., MD, Sobieski, Michael A., CCP, Gallagher, Collen, RN, Dia, Muhyaldeen, MD, Silver, Marc A., MD. Low Incidence of Neurologic Events during Long-Term Support with the HeartMate® XVE Left Ventricular Assist Device. *Tex Heart Inst J*. 2008; 35(3): 245–249.
75. Thoratec Corporation. Heartmate 3™ Left Ventricular Assist System Instructions for Use. Document: 100176253.A. Publication Date: 12/2020. ©2020 Thoratec Corporation.
76. Torregrossa G, Morshuis M, Varghese R, Hosseinian L, Vida V, Tarzia V, Loforte A, Duveau D, Arabia F, Leprince P, Kasirajan V, Beyersdorf F, Musumeci F, Hetzer R, Krabatsch T, Gummert J, Copeland J, Gerosa G. Results with SynCardia total artificial heart beyond 1 year. *ASAIO J*. 2014 Nov-Dec;60(6):626-34. doi: 10.1097/MAT.000000000000132.
77. UpToDate. Intermediate- and long-term mechanical circulatory support. 2020. Accessed at [uptodate.com](http://uptodate.com).
78. UpToDate. Short-term mechanical circulatory assist devices. 2025. Accessed at [uptodate.com](http://uptodate.com).
79. UpToDate. Treatment of advanced heart failure with a durable mechanical circulatory support device. 2025. Accessed at [uptodate.com](http://uptodate.com).
80. Uriel N, Colombo PC, et al. Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure. *Circulation*. 2017 May 23;135(21):2003-2012.
81. U.S. Food and Drug Administration 510(k) Summary K110493 (09/20/11): TandemHeart® System. Accessed at: <http://www.fda.gov>.
82. U.S. Food and Drug Administration Approval Order P170011 (09/20/17): Impella RP® System. Accessed at: <http://www.fda.gov>.
83. U.S. Food and Drug Administration Approval Order P030011 (10/15/04): Syncardia temporary CardioWest Total Artificial Heart (TAH-t). Accessed at: <http://www.fda.gov>.
84. U.S. Food and Drug Administration Approval Summary P160054 (08/23/17): HeartMate III® Left Ventricular Assist System. Accessed at: <http://www.fda.gov>.
85. U.S. Food and Drug Administration Approval Summary P100047/S090 (09/27/17): HeartWare™ HVAD™ System. Accessed at: <http://www.fda.gov>.
86. U.S. Food and Drug Administration Approval Summary P140003 (03/23/15): Impella 2.5 System. Accessed at: <http://www.fda.gov>.
87. U.S. Food and Drug Administration Approval Summary P140003/S018 (02/07/18): Impella Ventricular Support Systems. Accessed at: <http://www.fda.gov>.
88. U.S. Food and Drug Administration Approval Summary H100004 (12/16/11): Berlin Heart EXCOR® Pediatric Ventricular Assist Device (VAD). Accessed at: <http://www.fda.gov>.
89. U.S. Food and Drug Administration Humanitarian Device Exemption (HDE) H030003 (02/25/04): DeBakey VAD® Child Left Ventricular Assist System. Accessed at: <http://www.fda.gov>.
90. U.S. Food and Drug Administration Humanitarian Device Exemption (HDE) H030003/S009 (04/15/10): DeBakey VAD® Child Left Ventricular Assist System. Accessed at: <http://www.fda.gov>.
91. U.S. Food and Drug Administration Humanitarian Device Exemption (HDE) H040006 (09/05/06): AbioCor™ Implantable Replacement Heart. Accessed at: <http://www.fda.gov>.

92. U.S. Food and Drug Administration Humanitarian Device Exemption (HDE) H070004 (10/07/08): Levitronix CentriMag® Right Ventricular Assist System (RVAS). Accessed at: <http://www.fda.gov>.
93. U.S. Food and Drug Administration Premarket Approval P060040/S005 (01/20/10): Thoratec HeartMate H® Left Ventricular Assist System (LVAS). Accessed at: <http://www.fda.gov>.
94. U.S. Food and Drug Administration PMA Supplement P140003 (12/01/16): Impella Ventricular Support System. Accessed at: <http://www.fda.gov>.
95. U.S. Food and Drug Administration Approval Summary P160054/S031 (12/17/20): HeartMate 3 Left Ventricular Assist System. Accessed at: <http://www.fda.gov>.
96. Van Iterson EH. Left Ventricular Assist Device Support Complicates the Exercise Physiology of Oxygen Transport and Uptake in Heart Failure. *Card Fail Rev.* 2019;5(3):162-168. Published 2019 Nov 4. doi:10.15420/cfr.2019.10.2.

### COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 01/22/26.

### GUIDELINE UPDATE INFORMATION:

01/01/01	Medical Coverage Guideline developed.
01/01/02	Annual HCPCS coding update.
09/15/03	Reviewed; revised to delete investigational statement regarding VADs used for destination therapy and add coverage criteria for this indication; added new HCPCS codes for VADs; added clarification for VADs vs. artificial heart devices.
08/15/04	Scheduled review; revised title to include total artificial hearts; added procedure codes for artificial hearts.
05/15/05	Revision to add clarification regarding artificial heart or mechanical devices.
08/15/05	Scheduled review; no change in coverage statement.
08/15/06	Scheduled review (consensus review); no change in coverage statement.
07/15/07	Scheduled review; revised Description section; reformatted guideline; updated references.
07/15/08	Scheduled review; no change to position statement. Add CMS language for clinical trials. Update references. Update Internet links.
01/01/09	Annual HCPCS coding update: update descriptor 0048T; delete 0049T.
07/15/09	Scheduled review; no change in position statement. Update references.
01/01/10	Annual HCPCS coding update: add CPT codes 93750, 33981, 33982, & 33983 and HCPCS code Q0506; remove code range Q0480 – Q0505 and add codes with full descriptors for all replacement parts and accessories.
10/15/10	Revision; related ICD-10 codes added.
01/01/11	Annual HCPCS coding update. Added codes Q0478, Q0479. Revised descriptor for code Q0499.
10/15/11	Unscheduled review. Revised description section, position statement, CPT coding, ICD10 coding and definitions. Deleted Medicare Exception and updated references.

01/01/13	Annual CPT/HCPCS coding update. Added 33990, 33991, 33992 and 33993. Revised descriptor for 93750. Deleted 0048T and 0050T. Corrected descriptors for Q0478 and Q0479.
04/01/13	2nd quarter HCPCS coding update. Added Q0507, Q0508 and Q0509. Deleted Q0505.
06/15/13	Unscheduled review. Revised description section, position statement and program exceptions section. Updated references and reformatted guideline.
07/01/14	Deleted codes 92970 , 92971, 93750, Q0478, Q0479, Q0480, Q0481, Q0482, Q0483, Q0484, Q0485, Q0486, Q0487, Q0488, Q0489, Q0490, Q0491, Q0492, Q0493, Q0494, Q0495, Q0496, Q0497, Q0498, Q0499, Q0500, Q0501, Q0502, Q0503, Q0504, Q0506, Q0507, Q0508 and Q0509.
11/01/15	Revision: ICD-9 Codes deleted.
03/15/16	Scheduled review. Revised description section and index terms. Maintained position statement. Updated references. Reformatted guideline.
01/01/17	Annual CPT/HCPCS update. Added 0451T, 0452T, 0453T, 0454T, 0455T, 0456T, 0457T, 0458T, 0459T, 0460T, 0461T, 0462T, 0463T.
03/15/17	Scheduled review. Revised description section, coverage for rVAD, index terms, and program exceptions section. Updated references. Reformatted guideline.
08/15/17	Revision: updated description section. Added additional coverage indications for percutaneous VAD. Added HCPCS codes Q0478, Q0479, Q0480, Q0481, Q0482, Q0483, Q0484, Q0485, Q0486, Q0487, Q0488, Q0489, Q0490, Q0491, Q0492, Q0493, Q0494, Q0495, Q0496, Q0497, Q0498, Q0499, Q0500, Q0501, Q0502, Q0503, Q0504, Q0506, Q0507, Q0508 and Q0509. Revised index terms. Updated references.
12/15/17	Revision: added the HeartMate III® device and its FDA approved indications to the list of available mechanical circulatory support devices. Updated references.
01/01/18	Annual CPT/HCPCS coding update: added 33927, 33928, 33929, Q0477; deleted 0051T, 0052T, 0053T.
08/15/18	Revision: updated FDA approved indications and references.
01/01/19	Annual CPT/HCPCS coding update. Added L8698.
05/16/19	Revision: updated FDA approval indications for HeartMate III Left Ventricular Assist System and references.
08/15/20	Scheduled review. Revised description. Maintained position statement and updated references.
01/01/21	Annual CPT/HCPCS coding update. Revised 33990, 33991, 33992, 33993; added 33995, 33997.
11/15/21	Revision. Updated FDA approved indications for the HeartMate 3™ Left Ventricular Assist System. Updated references.
01/01/22	Annual CPT/HCPCS coding update. Deleted 0451T, 0452T, 0453T, 0454T, 0455T, 0456T, 0457T, 0458T, 0459T, 0460T, 0461T, 0462T, 0463T.
02/15/22	Scheduled review. Revised criteria for implantable VAD/destination therapy and definitions. Updated references.
05/25/23	Update to Program Exceptions section.
02/15/24	Scheduled review. Revised description, revised and reformatted Other section, maintained position statement, and updated references.

02/15/25	Scheduled review. Revised description, maintained position statement and updated references.
02/15/26	Scheduled review. Maintained position statement and updated references.